INVESTMENT AGREEMENTInvestment Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • Nevada
This Investment Agreement (this “Agreement”) is made and entered as of December 20, 2013 (the “Effective Date”) by and between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”), and Potomac Construction Limited (the “Investor”).
October 15, 2014Investment Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
Reference is hereby made to that certain Investment Agreement (the “Agreement”), dated as of May 30, 2013, between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”) and Potomac Construction Limited (“Investor”). This letter agreement will confirm the understanding and agreement of the undersigned parties regarding the interpretation and application of certain terms of the Agreement. Capitalized terms that are used but not defined herein have the meanings ascribed to them in the Agreement.
AMENDED AND RESTATED INTEREST AGREEMENTInterest Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • Nevada
This Amended and Restated Interest Agreement (this “Agreement”) is entered into on October 24, 2016 (the “Execution Date”), and made effective as of September 22, 2015 (the “Effective Date”), by and between LIGHTLAKE THERAPEUTICS INC., a Nevada corporation (the “Company”), and Valour Fund, LLC, a Delaware limited liability company and successor in interest to this Agreement (“Valour”).
Ernst Welmers Markham, Ontario, Canada Re: Investment Agreement Dear Ernst:Investment Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
Reference is hereby made to that certain Investment Agreement (the “Agreement”), dated as of May 15, 2014, between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”) and Ernst Welmers (“Investor”). This letter agreement will confirm the understanding and agreement of the undersigned parties regarding the interpretation and application of certain terms of the Agreement. Capitalized terms that are used but not defined herein have the meanings ascribed to them in the Agreement.
REGULATORY AND STRATEGIC ADVISOR CONSULTANCY AGREEMENTConsultancy Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
THIS Consultancy Agreement (the “Agreement”) is entered into by and between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”), and Mary Pendergast (the “Advisor”), effective as of September 1, 2015 (the “Effective Date”).
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • Nevada
This Amended and Restated Consulting Agreement (the “Agreement”) is entered into on October 25, 2016 (the “Execution Date”), and made effective as of July 17, 2013 (the “Effective Date”), by and between LYL Holdings Inc., a corporation and successor in interest to this Agreement (the “Consultant”), and Opiant Pharmaceuticals, Inc., a Nevada corporation (the “Company”).
INVESTMENT AGREEMENTInvestment Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • Nevada
This Investment Agreement (this “Agreement”) is made and entered as of December 8, 2015 (the “Effective Date”) by and between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”), and Potomac Construction Limited (the “Investor”).
Potomac Construction Limited Toronto, Ontario M6A 2A4 Canada Re: Investment Agreement Dear Potomac Construction Limited:Investment Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
Reference is hereby made to that certain Investment Agreement (the “Agreement”), dated as of October 31, 2014, between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”) and Potomac Construction Limited (“Investor”). This letter agreement will confirm the understanding and agreement of the undersigned parties regarding the interpretation and application of certain terms of the Agreement. Capitalized terms that are used but not defined herein have the meanings ascribed to them in the Agreement.
AMENDED AND RESTATED INTEREST AGREEMENTInterest Agreement • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • Nevada
This Amended and Restated Interest Agreement (this “Agreement”) is entered into on October 24, 2016 (the “Execution Date”), and made effective as of July 22, 2014 (the “Effective Date”), by and between OPIANT PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), and Valour Fund, LLC, a Delaware limited liability company and successor in interest to this Agreement (“Valour”).
18th December 2014 Dr. Roger Crystal Chief Executive Officer Lightlake Therapeutics Inc. London W1U 6TJ United Kingdom Dear Roger,Engagement Letter • October 28th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • London
This letter (“Engagement Letter” or “Agreement”), which takes effect from the 1st June 2014, confirms our agreement with Lightlake Therapeutics Inc. (including affiliates and assignees, the “Company”, “Lightlake” or “you”) with respect to the engagement of TORREYA PARTNERS (EUROPE) LLP (including affiliates and assignees, the “Advisor”, “Torreya”, “we” or “us”), to provide financial advisory services with regard to the licensing (“Licensing” or “Transaction”) of the intellectual and property rights to develop and commercialize Products with Adapt Pharma Operations Limited (“Partner”). “Product” means any pharmaceutical product in combination with a medical device, whether prescription or over-the-counter, containing naloxone, alone or in combination with one or more other active or inactive ingredients, in any intranasal form, presentation, strength or delivery systems for a treatment to reverse opioid overdose.
